Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson Sells 3,435 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 3,435 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $11.10, for a total transaction of $38,128.50. Following the transaction, the chief financial officer now owns 95,263 shares in the company, valued at $1,057,419.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Molly Henderson also recently made the following trade(s):

• On Friday, January 19th, Molly Henderson sold 6,307 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $7.75, for a total value of $48,879.25.

Phathom Pharmaceuticals Stock Performance

Shares of PHAT opened at $10.47 on Friday. The firm’s 50-day moving average is $9.31 and its two-hundred day moving average is $8.77. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $17.02.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.12. The firm had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.93 million. During the same quarter in the prior year, the company earned ($1.33) EPS. On average, sell-side analysts predict that Phathom Pharmaceuticals, Inc. will post -4.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Swiss National Bank boosted its position in shares of Phathom Pharmaceuticals by 7.7% in the 1st quarter. Swiss National Bank now owns 33,400 shares of the company’s stock worth $455,000 after buying an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Phathom Pharmaceuticals by 1.7% in the first quarter. JPMorgan Chase & Co. now owns 175,562 shares of the company’s stock valued at $2,389,000 after purchasing an additional 3,001 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Phathom Pharmaceuticals by 3.3% in the first quarter. Bank of New York Mellon Corp now owns 61,288 shares of the company’s stock valued at $834,000 after purchasing an additional 1,948 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of Phathom Pharmaceuticals by 58.5% in the first quarter. MetLife Investment Management LLC now owns 12,302 shares of the company’s stock valued at $167,000 after purchasing an additional 4,540 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Phathom Pharmaceuticals by 16.0% during the 1st quarter. Rhumbline Advisers now owns 19,968 shares of the company’s stock worth $272,000 after purchasing an additional 2,761 shares in the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a “buy” rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a research note on Thursday.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.